Showing results (251-260 of 297) with videos related to

Sort By:
Pageof 30
BMC Musculoskeletal Disorders|February 8, 2012
Pressure and pain in systemic sclerosis/scleroderma--an evaluation of a simple intervention (PISCES): randomised controlled trial protocolBegonya Alcacer-Pitarch, Maya H Buch, Janine Gray, et al.
Rheumatology Advances in Practice|February 5, 2021
Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiativeGabriele De Marco, Anna Berekméri, Laura C Coates, et al.
Nature Genetics|May 27, 2008
Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathySandeep Uppal, Christine P Diggle, Ian M Carr, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
GRAPPA 2019 Project ReportNiti Goel, Laura C Coates, Gabriele De Marco, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritisWilliam Tillett, Gavin Shaddick, Amelia Jobling, et al.
Rheumatology (Oxford, England)|February 8, 2020
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)Vinod Chandran, Désirée van der Heijde, Roy M Fleischmann, et al.
The Journal of Rheumatology|June 3, 2014
Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual MeetingMaarten de Wit, Willemina Campbell, Oliver FitzGerald, et al.
The Journal of Rheumatology|May 5, 2007
Outcome measures in psoriatic arthritisDafna D Gladman, Philip J Mease, Paul Healy, et al.
Rheumatology (Oxford, England)|June 29, 2022
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritisLaura C Coates, Christopher T Ritchlin, Laure Gossec, et al.
Rheumatology (Oxford, England)|September 1, 2020
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritisLaura C Coates, Joseph F Merola, Philip J Mease, et al.
Pageof 30